Results 61 to 70 of about 9,730 (212)

A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode

FEBS Open Bio, 2019
Human dihydroorotate dehydrogenase (DHODH), the enzyme that catalyzes the rate‐limiting step in de novo pyrimidine biosynthesis, is considered to be an attractive target for potential treatment of autoimmune disease and cancer.
Ting Zeng, Zeping Zuo, Youfu Luo, Yinglan Zhao, Yamei Yu, Qiang Chen   +5 more
doaj   +1 more source

Teriflunomide Does Not Change Dynamics of Nadph Oxidase Activation and Neuronal Dysfunction During Neuroinflammation

Frontiers in Molecular Biosciences, 2020
The multiple sclerosis therapeutic teriflunomide is known to block the de novo synthesis of pyrimidine in mitochondria by inhibiting the enzyme dihydroorotate-dehydrogenase (DHODH).
Ronja Mothes, Ronja Mothes, Carolin Ulbricht, Carolin Ulbricht, Ruth Leben, Robert Günther, Anja E. Hauser, Anja E. Hauser, Helena Radbruch, Raluca Niesner, Raluca Niesner   +10 more
doaj   +1 more source

Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma

Cell Death and Disease, 2021
Metabolic reprogramming is an integral part of the growth-promoting program driven by the MYC family of oncogenes. However, this reprogramming also imposes metabolic dependencies that could be exploited therapeutically. Here we report that the pyrimidine
Yajie Yu, Jane Ding, Shunqin Zhu, Ahmet Alptekin, Zheng Dong, Chunhong Yan, Yunhong Zha, Han-Fei Ding   +7 more
doaj   +1 more source

Dihydroorotate dehydrogenase in oxidative phosphorylation and cancer

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2020
Dihydroorotate dehydrogenase (DHODH) is an enzyme of the de novo pyrimidine synthesis pathway that provides nucleotides for RNA/DNA synthesis essential for proliferation. In mammalian cells, DHODH is localized in mitochondria, linked to the respiratory chain via the coenzyme Q pool.
Boukalova, Stepana, Hubackova, Sona, Milosevic, Mirko, Ezrova, Zuzana, Neuzil, Jiri, Rohlena, Jakub   +5 more
openaire   +3 more sources

Biomimetic Nanoplatform for Targeted Glioblastoma Therapy via Concurrently Triggering GPX4/DHODH Mediated Ferroptosis

Advanced Science, EarlyView.
Considering the great challenge in Glioblastoma multiforme (GBM) treatment, the authors designed and synthesized a multifunctional nanoplatform that effectively induced ferroptosis by synergetically inhibiting intrinsic intrisinc anti‐ferroptosis proteins, GPX4 & DHODH, and realized excellent in vitro and in vivo anti‐GBM effect.
Guodong Ren, Xuewei Wang, Panpan Li, Hao Wu, Zhifei Bi, Qi Gao, Bolong Ma, Zixuan Tian, Jianfei Liu, Fuqiang Feng, Wen Liu, Lin Li, Chengwu Zhang   +12 more
wiley   +1 more source

The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth [PDF]

, 2017
Cutaneous melanoma, which develops from the pigment producing cells called melanocytes, is the most deadly form of skin cancer. Unlike the majority of other cancers, the incidence rates of melanoma are still on the rise and the treatment options ...
Ascierto, Becker, Bushman, Chandra, Chapman, Chou, Cui, D’Andrea, Garraway, Hedstrom, Hoos, James, Jemal, Kaplan, Kim, Kramer, Lawrence, Lebbe, Loew-Friedrich, Long, Luke, Lutzky, Mauch, McArthur, Mocellin, Murray, Neyns, Patel, Rasty, Schmidmaier, Sherwood, Simmonds, Smalley, Talalay, Tanaka, Toker, Tsang, Wagstaff, Wargo, Wheeler, Yelon, Youle   +41 more
core   +5 more sources

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease. [PDF]

, 2017
F901318 is an antifungal agent with a novel mechanism of action and potent activity against Aspergillus spp. An understanding of the pharmacodynamics (PD) of F901318 is required for selection of effective regimens for study in phase II and III clinical ...
Adam Johnson, Anthony Kennedy, Derek Law, Joanne Livermore, John H. Rex, Julie Schwartz, Laura McEntee, Michael Birch, Nicola Farrington, Robert A. Bonomo, Ruwanthi Kolamunnage-Dona, Sarah Whalley, William W. Hope   +12 more
core   +2 more sources

Biosynthetic Dihydroorotate Dehydrogenase from Lactobacillus bulgaricus [PDF]

Journal of Bacteriology, 1971
This paper describes the first detailed study on a dihydroorotate dehydrogenase involved in pyrimidine biosynthesis. In most organisms the enzyme is membrane-bound; however, a soluble dihydroorotate dehydrogenase was produced in relatively high levels when the anaerobe, Lactobacillus bulgaricus , was released from ...
M L, Taylor, W H, Taylor, D F, Eames, C D, Taylor   +3 more
openaire   +2 more sources

The continuing significance of chiral agrochemicals

Pest Management Science, Volume 81, Issue 4, Page 1697-1716, April 2025.
In the time frame 2018–2023, around 43% of the 35 chiral agrochemicals introduced to the market (herbicides, fungicides, insecticides, acaricides, and nematicides) contain one or more stereogenic centers in the molecule, and almost 69% of them have been marketed as racemic mixtures of enantiomers or stereoisomers.
Peter Jeschke
wiley   +1 more source